Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
-
Vera Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
-
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
-
Vera Therapeutics announces proposed public offering of Class A common stock.
-
Vera Therapeutics appoints veteran biotech executive James R. Meyers to its Board of Directors.
-
Vera Therapeutics' management team will present and participate in one-on-one meetings at upcoming investor conferences.
-
Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).
-
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN
-
Vera Therapeutics to host an investor call and Webcast to provide an ORIGIN 3 update on November 6, 2025 at 4:30 pm ET.